Shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) Bounce After Obtaining GRAS Status for SONOVA® GLA Safflower Oil

Shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) Bounce After Obtaining GRAS Status for SONOVA® GLA Safflower Oil

Agricultural technology company, Arcadia Biosciences, Inc. (NASDAQ:RKDA), has obtained “generally recognized as safe” status from U.S. Food and Drug Administration. DAVIS, Calif.–(BUSINESS WIRE)– Arcadia Biosciences, Inc. (RKDA), an agricultural technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted Arcadia’s conclusion that its SONOVA® GLA safflower oil is “generally recognized as safe” (GRAS) for use in nutritional beverages and medical foods. Arcadia produces GLA safflower nutritional […]

Read More ˃
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) on the Rise Following Clearance of Phase III Study By USFDA

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) on the Rise Following Clearance of Phase III Study By USFDA

Leading developer of placenta-based cell therapy products, Pluristem Therapeutics, Inc. (NASDAQ:PSTI), has announced that its Phase III PLX-PAD study has been approved by the U.S. Food and Drug Administration. HAIFA, Israel, Jan. 10, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, today announced that the Company’s Phase III study of its PLX-PAD cells in the treatment of critical limb ischemia (CLI) […]

Read More ˃
Shares of xG Technology, Inc. (NASDAQ:XGTI) on the Rise After Regaining Compliance with Nasdaq Listing Requirements

Shares of xG Technology, Inc. (NASDAQ:XGTI) on the Rise After Regaining Compliance with Nasdaq Listing Requirements

Leading provider of critical wireless communications for use in challenging operating environments, xG Technology, Inc. (NASDAQ:XGTI), announces it has regained compliance with Nasdaq listing requirements. SARASOTA, Fla., Jan. 10, 2017 /PRNewswire/ — xG Technology, Inc. (“xG” or the “Company”) (Nasdaq: XGTI, XGTIW), a leader in providing critical wireless communications for use in challenging operating environments, announced today that the Company has regained full compliance with all listing requirements of the […]

Read More ˃
Akers Biosciences, Inc. (NASDAQ:AKER) Falls on News of Pricing of Public Offering

Akers Biosciences, Inc. (NASDAQ:AKER) Falls on News of Pricing of Public Offering

Developer of rapid health information technologies, Akers Biosciences, Inc. (NASDAQ:AKER), has announced an agreement to sell over 1.6 million shares of common stock. THOROFARE, NJ–(Marketwired – Jan 9, 2017) – Akers Biosciences, Inc. ( NASDAQ : AKER ) ( AIM : AKR.L ), (the “Company” or “Akers Bio”), a developer of rapid health information technologies, today announces the entry into an agreement relating to the sale of 1,667,000 shares of […]

Read More ˃
hhgregg, Inc. (NYSE:HGG) Plunges over 40% Following Announcement of Preliminary Q3 Net Sales

hhgregg, Inc. (NYSE:HGG) Plunges over 40% Following Announcement of Preliminary Q3 Net Sales

Appliance, electronics and furniture retailer that is committed to providing customers with a truly differentiated purchase experience through superior customer service, knowledgeable sales associates and the highest quality product selections, hhgregg, Inc. (NYSE:HGG), releases preliminary Q3 fiscal results. INDIANAPOLIS–(BUSINESS WIRE)– hhgregg, Inc. (“hhgregg” or the “Company”) (HGG) today announced preliminary net sales results for the third fiscal quarter ended December 31, 2016. The Company also announced information on certain non-cash […]

Read More ˃
Shares of Biocept, Inc. (NASDAQ:BIOC) Skyrocket on News it Has Secured Provider Agreement with Blue Cross Blue Shield of Texas

Shares of Biocept, Inc. (NASDAQ:BIOC) Skyrocket on News it Has Secured Provider Agreement with Blue Cross Blue Shield of Texas

Leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, Biocept, Inc. (NASDAQ:BIOC), has finalized an in-network provider agreement with Texas’ largest provider of health benefits, Blue Cross Blue Shield of Texas. SAN DIEGO, Jan. 10, 2017 /PRNewswire/ — Biocept, Inc. (BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that it […]

Read More ˃
Vapor, Corp. (OTCMKTS:VPCO) Announces Extension of Cash Tender Offer, How Will the Market Respond?

Vapor, Corp. (OTCMKTS:VPCO) Announces Extension of Cash Tender Offer, How Will the Market Respond?

U.S. based retailer of vaporizers, e-liquids and electronic cigarettes, operating thirteen stores in the Southeast and online, Vapor, Corp. (OTCMKTS:VPCO), has announced an extension of its cash tender offer. HOLLYWOOD, Fla., Jan. 9, 2017 /PRNewswire/ — Vapor Corp. (OTC Pink: VPCO) (“Vapor” or the “Company”) announced today that it has extended its previously announced tender offer to purchase its outstanding Series A Warrants (the “Series A Warrants”), in accordance with […]

Read More ˃
Viking Therapeutics, Inc. (NASDAQ:VKTX) Announce Senior Level Appointments to Management Team as Shares Explode

Viking Therapeutics, Inc. (NASDAQ:VKTX) Announce Senior Level Appointments to Management Team as Shares Explode

Clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, Viking Therapeutics, Inc. (NASDAQ:VKTX), announces several new appointments to its senior level management team. SAN DIEGO, Jan. 5, 2017 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced several senior level appointments designed to strengthen the company’s leadership as […]

Read More ˃
Ex-Smashburger CEO, Scott Crane, Lands at Rave Restaurant Group, Inc. (NASDAQ:RAVE) as Share Price Advances

Ex-Smashburger CEO, Scott Crane, Lands at Rave Restaurant Group, Inc. (NASDAQ:RAVE) as Share Price Advances

Dallas, Texas-based owner, franchiser and supplier of more than 275 Pie Five and Pizza Inn restaurants operating domestically and internationally, Rave Restaurant Group, Inc. (NASDAQ:RAVE), announces it has named former top executive of Smashburger, Scott Crane, as CEO. Scott Crane, a top executive at Denver-based Smashburger for nine years, has been named CEO of the Texas-based parent company of the Pie Five Pizza and Pizza Inn chains. Crane will lead […]

Read More ˃
$50M deal: ProPhase Labs, Inc. (NASDAQ:PRPH) Selling Cold-Eeze Brand, How Will Share Price Be Affected?

$50M deal: ProPhase Labs, Inc. (NASDAQ:PRPH) Selling Cold-Eeze Brand, How Will Share Price Be Affected?

Diversified natural health science company, ProPhase Labs, Inc. (NASDAQ:PRPH), announces it has sold its Cold-Eeze brand to a subsidiary of Mylan N.V. for a price of $50 million. ProPhase Labs Inc. has entered into an agreement to sell its Cold-Eeze cold remedy brand to a wholly owned subsidiary of Mylan N.V. for $50 million. The Philadelphia Business Journals first reported the Doylestown company was exploring the potential sale of the […]

Read More ˃
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Announces Successful Completion of Scientific Advice Discussions, How Will the Market Respond?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Announces Successful Completion of Scientific Advice Discussions, How Will the Market Respond?

Clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, CymaBay Therapeutics, Inc. (NASDAQ:CBAY), reveals that it has completed its scientific advice discussions with European Medicines Agency on its Phase 3 development program. NEWARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced […]

Read More ˃
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on the Rise Following News of Alliance With Servier

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on the Rise Following News of Alliance With Servier

Clinical-stage biotechnology company advancing novel biotherapeutics, Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), announces that it has reached an alliance with Servier, an independent international pharmaceutical company from France. BOSTON, MA and SURESNES, FRANCE–(Marketwired – January 05, 2017) –     Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris’ proprietary dual checkpoint inhibitor PRS-332 […]

Read More ˃
Shares of O2Micro International, Ltd. (NASDAQ:OIIM) Spike Following its Revision of Fourth Quarter 2016 Financial Guidance

Shares of O2Micro International, Ltd. (NASDAQ:OIIM) Spike Following its Revision of Fourth Quarter 2016 Financial Guidance

Global leader in the design, development and marketing of high-performance integrated circuits and solutions, O2Micro International, Ltd. (NASDAQ:OIIM), has revised its guidance for the Q4 2016, invigorating investors. GEORGE TOWN, Grand Cayman, Jan. 04, 2017 (GLOBE NEWSWIRE) — O2Micro® International Limited (OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, today revised its guidance for the fourth quarter of 2016. The company now […]

Read More ˃
Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) Climb Following Release of Data Demonstrating Benefit for Gimoti in Phase 3 Diabetic Gastroparesis Trial

Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) Climb Following Release of Data Demonstrating Benefit for Gimoti in Phase 3 Diabetic Gastroparesis Trial

Specialty pharmaceutical company focused on treatments for gastrointestinal diseases, Evoke Pharma, Inc. (NASDAQ:EVOK), provided positive new data from the Phase 3 trial of Gimoti. SOLANA BEACH, CA, Jan. 04, 2017 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided additional data from the Phase 3 trial of Gimoti, its nasal delivery of metoclopramide for the relief of symptoms associated […]

Read More ˃
Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in the Tank After Law Offices of Howard G. Smith Commence Investigation on Behalf of Investors

Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in the Tank After Law Offices of Howard G. Smith Commence Investigation on Behalf of Investors

Specialty pharmaceutical company that focuses on the development and commercialization of prescription contraceptive products for women, Agile Therapeutics, Inc. (NASDAQ:AGRX), is under investigation for potential violation of federal securities laws. BENSALEM, Pa.–(BUSINESS WIRE)– Law Offices of Howard G. Smith announces an investigation on behalf of investors of Agile Therapeutics, Inc. (“Agile” or the “Company”) (NASDAQ: AGRX) concerning the Company and its officers’ potential violation of federal securities laws. Agile is […]

Read More ˃
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Advance Following Announcement of Exclusive Licensing Agreement with Kowa Pharmaceuticals

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Advance Following Announcement of Exclusive Licensing Agreement with Kowa Pharmaceuticals

Clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, CymaBay Therapeutics, Inc. (NASDAQ:CBAY), announces that it has entered into an exclusive license agreement with Kowa Pharmaceuticals America, Inc. NEWARK, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it has entered […]

Read More ˃
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Up Following Announcement of New Patient-Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Up Following Announcement of New Patient-Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss

Biopharmaceutical company focused on the treatment of obesity, Orexigen Therapeutics, Inc. (NASDAQ:OREX), has launched a new advertising campaign demonstrating what role the brain plays in weight loss. SAN DIEGO, Jan. 3, 2017 /PRNewswire/ — Orexigen Therapeutics, Inc. (OREX) unveiled “Brains Behind Weight Loss,” a new, national direct-to-consumer advertising campaign demonstrating to patients how the brain plays an important role in weight loss. The campaign will underscore how CONTRAVE (naltrexone HCl/bupropion […]

Read More ˃
Inotek Pharmaceuticals, Corp. (NASDAQ:ITEK) Craters Over 71% Following Failure of Phase 3 Trial

Inotek Pharmaceuticals, Corp. (NASDAQ:ITEK) Craters Over 71% Following Failure of Phase 3 Trial

Clinical-stage biopharmaceutical company focused on diseases of the eye, Inotek Pharmaceuticals, Corp. (NASDAQ:ITEK), goes in the tank after failure of Phase 3 trial.  Investors in Inotek Pharmaceuticals (NASDAQ:ITEK), a clinical-stage biopharma focused on diseases of the eye, are having a tough start to the new year. Shares are collapsing in early-morning trading on Tuesday, falling more than 68% as of 10:05 a.m EST after the company reported results from a […]

Read More ˃
Cempra, Inc. (NASDAQ:CEMP) Shares Tank Following Concerns of Drug Approval Delay

Cempra, Inc. (NASDAQ:CEMP) Shares Tank Following Concerns of Drug Approval Delay

Clinical-stage drug company, Cempra, Inc. (NASDAQ:CEMP), was informed by the USFDA that it cannot approve its newest drug without additional data. Shares of clinical-stage drug company Cempra Inc. cratered Thursday, after the U.S. Food and Drug Administration said it cannot approve a pneumonia drug without additional safety data and improvements at a manufacturing facility. Shares of the Chapel Hill, N.C.–based company closed down 57% to $2.60, boosting year-to-date losses to […]

Read More ˃
Tetralogic Pharmaceuticals, Corp. (OTCMKTS:TLOG) Explodes Following Announcement of Completion of Sale

Tetralogic Pharmaceuticals, Corp. (OTCMKTS:TLOG) Explodes Following Announcement of Completion of Sale

Clinical-stage pharmaceutical company, Tetralogic Pharmaceuticals, Corp. (OTCMKTS:TLOG), announces that, alongside its subsidiary TetraLogic Research and Development Corporation, it has completed a sale for $12 million. PAOLI, Pa., Dec. 29, 2016 (GLOBE NEWSWIRE) — TetraLogic Pharmaceuticals Corporation (TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic program, including […]

Read More ˃